共 125 条
[1]
Bani-Sadr F(2007)Early virologic failure in HIV-coinfected hepatitis C patients treated with the peginterferon-ribavirin combination: does abacavir play a role? J Acquir Immune Defic Syndr 45 123-125
[2]
Denoeud L(2008)Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone J Antimicrob Chemother 62 1365-1373
[3]
Morand P(2008)Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir Antivir Ther 13 429-437
[4]
Lunel-Fabiani F(1999)The clinical pharmacology of ribavirin Semin Liver Dis 19 17-24
[5]
Pol S(2007)Influence of concomitant antiretroviral therapy on the rate of sustained virological response to pegylated interferon plus ribavirin in hepatitis C virus/HIV-coinfected patients J Antimicrob Chemother 60 1347-1354
[6]
Cacoub P(2008)Abacavir does not influence the rate of virological response in HIV-HCV-coinfected patients treated with pegylated interferon and weight-adjusted ribavirin Antivir Ther 13 953-957
[7]
Mira JA(2010)The influence of abacavir and other antiretroviral agents on virological response to HCV therapy among antiretroviral-treated HIV-infected patients Antivir Ther 15 91-99
[8]
Lopez-Cortes LF(2012)Ribavirin and abacavir drug interaction in HIV-HCV coinfected patients: fact or fiction? AIDS 26 2193-2199
[9]
Barreiro P(2011)Effect of accompanying antiretroviral drugs on virological response to pegylated interferon and ribavirin in patients co-infected with HIV and hepatitis C virus J Antimicrob Chemother 66 2843-2849
[10]
Tural C(2003)A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C Hepatology 38 518-526